%PDF-1.4
%
54 0 obj
<>
endobj
51 0 obj
<>
endobj
123 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-09T09:14:11Z
2024-03-28T17:28:06-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T17:28:06-07:00
application/pdf
Heather
2002-1061.oct
uuid:0c2bf8b1-1dd2-11b2-0a00-b509277d8900
uuid:0c2bf8b3-1dd2-11b2-0a00-d30000000000
endstream
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
55 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
149 0 obj
[154 0 R]
endobj
150 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(7.)-875 (Hurst NP)111 (, Jobanputra P)111 (, Hunter M, Lambert M, Lochhead )55 (A, Brown)]TJ
1.675 -1.25 Td
[(H. )18 (V)111 (alidity of Euroqol, a generic health status instrument, in)]TJ
0 -1.25 TD
(patients with rheumatoid arthritis. Economic and Health Outcomes)Tj
T*
(Research Group. Br J Rheumatol 1994;33:655-62.)Tj
-1.675 -1.25 Td
[(8.)-875 (Hurst NP)111 (, Kind P)111 (, Ruta D, Hunter M, Stubbings )55 (A. Measuring)]TJ
1.675 -1.25 Td
[(health-related quality of life in rheumatoid arthritis: validity)65 (,)]TJ
T*
(responsiveness and reliability of EuroQol \(EQ-5D\). Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:551-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Fransen M, Edmonds J. Reliability and validity of the EuroQol in)]TJ
1.675 -1.25 Td
(patients with osteoarthritis of the knee. Rheumatology)Tj
0 Tc 0 Tw T*
(1999;38:807-13.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875 (Brazier JE, Harper R, Munro J, )18 (W)80 (alters SJ, Snaith ML. Generic and)]TJ
2.175 -1.25 Td
(condition-specific outcome measures for people with osteoarthritis)Tj
T*
(of the knee. Rheumatology 1999;38:870-7.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (W)80 (olfe F)80 (, Hawley DJ. Measurement of the quality of life in)]TJ
2.1381 -1.25 Td
(rheumatic disorders using the EuroQol. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;36:786-93.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic )]TJ
2.175 -1.25 Td
(consequences of the progression of rheumatoid arthritis in Sweden.)Tj
T*
(Arthritis Rheum 1999;42:347-56.)Tj
-2.175 -1.25 Td
[(13.)-875 (W)80 (olfe F)80 (, Kong SX, )18 (W)80 (atson DJ. Gastrointestinal symptoms and)]TJ
2.175 -1.25 Td
(health related quality of life in patients with arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2000;27:1373-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (W)80 (ang C, Mayo NE, Fortin PR. )18 (The relationship between health)]TJ
2.175 -1.25 Td
(related quality of life and disease activity and damage in systemic)Tj
T*
(lupus erythematosus. J Rheumatol 2001;28:525-32.)Tj
-2.175 -1.25 Td
[(15.)-875 (Suarez-Almazor ME, Conner)20 (-Spady B. Rating of arthritis health)]TJ
2.175 -1.25 Td
(states by patients, physicians, and the general public. Implications)Tj
T*
(for cost-utility analyses. J Rheumatol 2001;28:648-56.)Tj
-2.175 -1.25 Td
[(16.)-875 (Sokoll KB, Helliwell PS. Comparison of disability and quality of)]TJ
2.175 -1.25 Td
(life in rheumatoid and psoriatic arthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1842-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Pipitone N, Scott DL. Magnetic pulse treatment for knee)]TJ
2.175 -1.25 Td
[(osteoarthritis: a randomised, double-blind, placebo-controlled study)65 (.)]TJ
T*
(Curr Med Res Opin 2001;17:190-6.)Tj
-2.175 -1.25 Td
[(18.)-875 (Moore )55 (AD, Clarke )55 (AE, Danof)18 (f DS, et al. Can health utility)]TJ
2.175 -1.25 Td
[(measures be used in lupus research? )55 (A)-220 (comparative validation and)]TJ
T*
(reliability study of 4 utility indices. J Rheumatol 1999;26:1285-90.)Tj
-2.175 -1.25 Td
[(19.)-875 (Grootendorst P)111 (, Feeny D, Furlong )18 (W)92 (. Health utilities index mark 3:)]TJ
2.175 -1.25 Td
(evidence of construct validity for stroke and arthritis in a )Tj
T*
[(population health survey)65 (. Med Care 2000;38:290-9.)]TJ
-2.175 -1.25 Td
[(20.)-875 (Raynauld JP)111 (, )18 (T)70 (orrance GW)92 (, Band P)92 (A, et al. )55 (A)-220 (prospective, )]TJ
2.175 -1.25 Td
(randomized, pragmatic, health outcomes trial evaluating the )Tj
T*
(incorporation of hylan G-F 20 into the treatment paradigm for)Tj
T*
(patients with knee osteoarthritis \(Part 1 of 2\): clinical results.)Tj
T*
(Osteoarthritis Cartilage 2002;10:506-17.)Tj
-2.175 -1.25 Td
[(21.)-875 (T)70 (orrance GW)92 (, Raynauld JP)111 (, )18 (W)80 (alker )18 (V)129 (, et al. )55 (A)-220 (prospective, )]TJ
2.175 -1.25 Td
(randomized, pragmatic, health outcomes trial evaluating the )Tj
T*
(incorporation of hylan G-F 20 into the treatment paradigm for)Tj
T*
(patients with knee osteoarthritis \(Part 2 of 2\): economic results.)Tj
T*
(Osteoarthritis Cartilage 2002;10:518-27.)Tj
-2.175 -1.25 Td
[(22.)-875 (Mittmann N, )18 (T)35 (rakas K, Risebrough N, Liu BA. Utility scores for)]TJ
2.175 -1.25 Td
(chronic conditions in a community-dwelling population.)Tj
T*
(Pharmacoeconomics 1999;15:369-76.)Tj
-2.175 -1.25 Td
[(23.)-875 (Statistics Canada. )55 (A)-220 (head-to-head comparison of two generic health)]TJ
2.175 -1.25 Td
(status measures in the household population: McMaster health )Tj
T*
(utilities index \(mark 3\) and the EQ-5D \(internal document\).)Tj
T*
(Ottawa: Statistics Canada; 2000.)Tj
-2.175 -1.25 Td
[(24.)-875 (Bosch JL, Hunink MG. Comparison of the health utilities index)]TJ
2.175 -1.25 Td
(mark 3 \(HUI3\) and the EuroQol EQ-5D in patients treated for)Tj
T*
(intermittent claudication. Qual Life Res 2000;9:591-601.)Tj
-2.175 -1.25 Td
[(25.)-875 (W)80 (are JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey)]TJ
2.175 -1.25 Td
[(manual and interpretation guide. Boston: )18 (The Health Institute, New)]TJ
T*
(England Medical Center; 1993.)Tj
-2.175 -1.25 Td
[(26.)-875 (W)80 (olfe F)80 (, Smythe HA, )37 (Y)111 (unus MB, et al. )18 (The )55 (American College of)]TJ
35.175 80 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia:)Tj
T*
[(report of the multicenter criteria committee. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1990;33:160-72.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Dolan P)111 (. Modeling valuations for EuroQol health states. Med Care)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1997;35:1095-108.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875 (Luo N, Chew LH, Fong KY)129 (, et al. )18 (V)111 (alidity and reliability of the)]TJ
2.175 -1.25 Td
[(EQ-5D self-reported questionnaire in English-speaking )55 (Asian)]TJ
T*
(patients with rheumatic diseases in Singapore. Qual Life Res)Tj
0 Tc 0 Tw T*
(2003;12:87-92.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875 (Luo N, Chew LH, Fong KY)129 (, et al. )18 (V)111 (alidity and reliability of the)]TJ
2.175 -1.25 Td
(EQ-5D self-reported questionnaire in Chinese-speaking patients)Tj
T*
[(with rheumatic diseases in Singapore. )55 (Ann )55 (Acad Med Singapore \(in)]TJ
0 Tw T*
(press\).)Tj
0.02499 Tw -2.175 -1.25 Td
[(30.)-875 (Luo N, Chew LH, Fong KY)129 (, et al. )55 (Are scores of Singaporean)]TJ
2.175 -1.25 Td
[(English and Chinese EQ-5D versions equivalent? )55 (An exploratory)]TJ
T*
[(study [abstract]. Qual Life Res 2002;1)37 (1:647.)]TJ
-2.175 -1.25 Td
[(31.)-875 (Keeney RL, Raif)18 (fa H. Decisions with multiple objectives: )]TJ
2.175 -1.25 Td
[(preference and value tradeof)18 (fs: Second Edition. New )37 (Y)100 (ork:)]TJ
T*
(Cambridge University Press; 1993.)Tj
-2.175 -1.25 Td
[(32.)-875 (Feeny D, Furlong )18 (W)92 (, )18 (T)70 (orrance GW)92 (, et al. Multi-attribute and)]TJ
2.175 -1.25 Td
(single-attribute utility functions for the health utilities index mark 3\
)Tj
T*
[(system. Med Care 2002;40:1)37 (13-28.)]TJ
-2.175 -1.225 Td
[(33.)-875 (W)80 (ang Q, Chen G. )18 (The health status of the Singaporean population)]TJ
2.175 -1.225 Td
(as measured by a multi-attribute health status system. Singapore)Tj
0 Tc 0 -1.225 TD
(Med J 1999;40:389-96.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(34.)-875 (W)80 (agner )55 (AK, Gandek B, )55 (Aaronson NK, et al. Cross cultural )]TJ
2.175 -1.225 Td
(comparisons of the content of SF-36 translations across 10 )Tj
T*
(countries: results from the international quality of life assessment)Tj
T*
(project. J Clin Epidemiol 1998;51:925-32.)Tj
-2.175 -1.225 Td
[(35.)-875 (Lam CL, Gandek B, Ren XS, Chan MS. )18 (T)70 (ests of scaling )]TJ
2.175 -1.225 Td
(assumptions and construct validity of the Chinese \(HK\) version of)Tj
T*
[(the SF-36 Health Survey)65 (. J Clin Epidemiol 1998;51:1)37 (139-47.)]TJ
-2.175 -1.225 Td
[(36.)-875 (Thumboo J, Fong KY)129 (, Machin D, et al. )55 (A)-220 (community-based study)]TJ
2.175 -1.225 Td
(of scaling assumptions and construct validity of the English \(UK\))Tj
T*
(and Chinese \(HK\) SF-36 in Singapore. Qual Life Res )Tj
0 Tc 0 Tw T*
(2001;10:175-88.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.225 Td
[(37.)-875 (Fayers PM, Machin D. Quality of life: )55 (Assessment, analysis and)]TJ
2.175 -1.225 Td
[(interpretation. Chichester: John )18 (W)40 (iley & Sons; 2000.)]TJ
-2.175 -1.225 Td
[(38.)-875 (Brazier J, Jones N, Kind P)111 (. )18 (T)70 (esting the validity of the Euroqol and)]TJ
2.175 -1.225 Td
(comparing it with the SF-36 health survey questionnaire. Qual Life)Tj
0 Tc T*
(Res 1993;2:169-80.)Tj
-0.00011 Tc -2.175 -1.225 Td
[(39.)-875 (Hawthorne G, Richardson J, Day NA. )55 (A)-220 (comparison of the )]TJ
2.175 -1.225 Td
(assessment of quality of life \(AQoL\) with four other generic utility)Tj
0 Tc T*
[(instruments. )55 (Ann Med 2001;33:358-70.)]TJ
-0.00011 Tc -2.175 -1.225 Td
[(40.)-875 (Revicki DA, Kaplan RM. Relationship between psychometric and)]TJ
2.175 -1.225 Td
(utility-based approaches to the measurement of health-related)Tj
T*
(quality of life. Qual Life Res 1993;2:477-87.)Tj
-2.175 -1.225 Td
[(41.)-875 (Boyle MH, Furlong )18 (W)92 (, Feeny D, )18 (T)70 (orrance GW)92 (, Hatcher J.)]TJ
2.175 -1.225 Td
(Reliability of the health utilities index\321mark III used in the 1991)Tj
T*
(cycle 6 Canadian General Social Survey Health Questionnaire.)Tj
T*
(Qual Life Res 1995;4:249-57.)Tj
-2.175 -1.225 Td
[(42.)-875 (Read JL, Quinn RJ, Berwick DM, Fineber)18 (g HV)129 (, )18 (W)80 (einstein MC.)]TJ
2.175 -1.225 Td
(Preferences for health outcomes. Comparison of assessment)Tj
T*
(methods. Med Decis Making 1984;4:315-29.)Tj
-2.175 -1.225 Td
[(43.)-875 (Bass EB, Steinber)18 (g EP)111 (, Pitt HA, et al. Comparison of the rating)]TJ
2.175 -1.225 Td
(scale and the standard gamble in measuring patient preferences for)Tj
T*
(outcomes of gallstone disease. Med Decis Making 1994;14:307-14.)Tj
-2.175 -1.225 Td
[(44.)-875 (Martin )55 (AJ, Glasziou PP)111 (, Simes RJ, Lumley )18 (T)74 (. )55 (A)-220 (comparison of)]TJ
2.175 -1.225 Td
[(standard gamble, time trade-of)18 (f, and adjusted time trade-of)18 (f scores.)]TJ
T*
[(Int J )18 (T)70 (echnol )55 (Assess Health Care 2000;16:137-47.)]TJ
-2.175 -1.225 Td
[(45.)-875 (Morimoto )18 (T)74 (, Fukui )18 (T)74 (. Utilities measured by rating scale, time )]TJ
2.175 -1.225 Td
[(trade-of)18 (f, and standard gamble: review and reference for health care)]TJ
T*
(professionals. J Epidemiol 2002;12:160-78.)Tj
-2.175 -1.25 Td
[(46.)-875 (T)70 (suchiya )55 (A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D )]TJ
2.175 -1.25 Td
(population value set: the case of Japan. Health Econ )Tj
0 Tc 0 Tw 0 -1.25 TD
[(2002;1)37 (1:341-53.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2274)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
34 0 obj
<>stream
8;Z\6!H,h0#ikq,j?)+u_)>"Ydb\!QUh/"hlVRc(5huCcs7om>m/-PSj7V[(pZKZa
=]cZ)g)#59nTri=H$dr!(D#hBfY06uTrTu:\%nHO&Z[$SYP(f6@c[-:Za&FT^aB!8
dlbEK$SPY!-crAFdW5U^B1-%!1TpMRePbFes.cFnN-PUYo^Q;0mEtNXY8ioT\J_oM
`D7&87":'jV;%%-p";Y]Ub'YZ9<5[H>_=_lZf^t<"5R2X?P96XD?pSjAI.qiNbb\E5O
:8FkXbRMQV$8a\hG4!3"20(>U>A?Y`gIcUKUdN@[M4R^R9D"*^mo\ps>N-_R*sR-:'PS(<]X#jmNB
IOfMjJN,=CRqj2t_hD/%UqVj[4ZcgppFHi<:?qR7L_)
SIi&"Bh0qkS`n7YD_ZS^6U;(N)n-?t-Sn&NFLg=\Nu?\k-F4oP.aFp&W>[-&0%V(u
U*c+u+IJn@"N9dajPD[(4#r]oW@Lt>B-YVZk5*".K,&*c"%NVi6?BdY8r4?RKX!f,
DNYI6N]/9k$E_H)/l]gteW.7nU4.da6/6.CM,.+RVFit+ablmlNa4jk!EgOo._BKI
7Wn`762plZ)?:)O++s~>
endstream
endobj
38 0 obj
[/Indexed/DeviceRGB 255 37 0 R]
endobj
37 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
62 0 obj
<>
endobj
57 0 obj
<>
endobj
98 0 obj
<>
endobj
128 0 obj
<>
endobj
58 0 obj
<>
endobj
91 0 obj
<>stream
H{PSWrq)[ꫫ""SA"H!H$@!H !@QQ@@e`U\RSTvU:?;g7g~f]& kv)cqfA0Y{FZ%.Z3hMz.+%ڲܱor_"qHԴ>_&du6~m.n%T&I]bIX iz[J
WJKR$Ӓ}wcZ(LO:X*4?5aXB-}Ҍ80Aȗ_{qn_1ܲ0[d/w6cVnY
#0*
??[Y]#\jbܚo=EړɬìyΦvwABbaQ[2zRo,V/dqej5%us?Sp].]\ܬy4JQ>pcϠܢvmc #+c95J77p+5Ar02J[,@ƫ~uRfh>Zlwrz7pFy/5FQGCc3%MM՚grew`k&W@+J=MM),+Vy"z^CM:i;.KwjOnL78}`RB2g|_[']\O+xȊ8R~dU/Ut
?h0!l* З.
`\4|3־LZO>OZ-WzA
QiIrz>YV,rW&W*>|2m|1`OF O}4/UT8TSUb6p>E0-ԼR!/ݠ9
$.B xf &Q|02Xp\s};gP5Q?ծ4mT(>-PRss*N
@a
ђʠ./Aքq`oo6=?S?ooOLb"87fue5
đ"Um[-$ն4DRڣuY=ߏ癳waAJFWm`Ux;%W<(f͓,+"-fV{#S=$QFLχMAa+&"8wBa{oʻ.'qwt75L$MsΡP8BIMnj7CUkBed
8C e6Z9}xܾ1-)K鋹n\v